Share |

Content about Microbiology

July 29, 2015

Treatment for chronic hepatitis B (CHB) has improved significantly in the last 10 years but despite those improvements  360 million people or 5 percent of the world’s population remain chronically infected by the Hepatitis B virus (HBV). That's according to Gaithersburg, Md-based Vaxin Inc, the company recently announced that it has initiated Phase 1 clinical stage trial to test a vaccine treatment for HepTcell, its' immunotherapeutic compound to treat people who are chronically infected with HBV.

July 20, 2015

Biodefense company Emergent BioSolutions (NYSE: EBS) won a large Biomedical Advanced Research and Development Authority (BARDA) contract to treat Ebola Monoclona.

The contract is the company's first BARDA Task Order to create an Ebola treatment under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. BARDA is an authority under the U.S. Department of Health and Human Services.

July 13, 2011

Annapolis based biotechnology company PharmAthene, Inc has reached a pivotal milestone in its development of an Anthrax prevention drug.

The biodefense biotech said that its SparVax™ rPA Anthrax Vaccineachieved a 36 month final product stability.